Ashley E. Ross, MD, PhD, recaps several presentations on prostate cancer from the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.
Patients with high-risk prostate cancer appeared to derive benefit from androgen deprivation therapy given for a minimal duration of over 18 months plus external beam radiotherapy.
Quality of life outcomes compared favorably with radical prostatectomy and radiotherapy, researchers said.
Adam Kibel, MD, discusses his presentation of a “grab bag of topics” at the AUA meeting.
Findings are published in the journal Science Translational Medicine.